Investor Slide Deck

Dr. Blair Bittner Toohey Chief Executive Officer drblair@stimcoremd.com

CPAP Obstructive Sleep Apnea

• Does Not Restore Airway Function

• 1% Specialist

• Poor Patient Compliance

Stimcore Medical Device Suite

Daytime Use

Restores Airway Function

Non-Invasive

Readily Accessible

Sinokair

Sinus

Anatomy Specific

Patient Friendly

Emerging Bioelectric Market

Orakair-S

Soft Palate

Orakair-T

Tongue & Throat

Wearable Smart Devices

Bioelectric

•

Stimcore Revenue and RecurringRevenue Model • (LTV) Patient$17,300 • (LTV) Doctor $46,200 Certification/ Training Modules $2500 One Time First Year Projection $2,500,000 • (COGS) $400 • (CAC) $180 Medical Device Sales $2200 (WAG) (2 Devices) First Year Projection $105,600,000 Patient Data Portal Subscription $840 Recurring Revenue First Year Projection $840,000

Non- surgical

Stimcore vs CPAP

Non - Surgical Treatment Options

Stimcore Medical Devices CPAP

Addresses Root Cause

Easy to Access

Patient Friendly

Daytime Use

Doctor Monitored

Preventive

Addresses Chronic Disease

UseOf Funds

Marketing Branding 15% $750,000 Pre Market Data 5% $250,000 510(k) 5% $250,000 Previous Raise: $1.46F&F Investors: 21 Raising $5,000,000 Seed Round

Engineering 15% $750,000 Hardware Development (Mechanical & Electronics) 15% $750,000 Software Firmware Secure Portal 15% $750,000 Prototyping Development 15% $750,000

Stimcore Management Team

CMO

CTO

Dr.Blair Bittner Toohey Stimcore Founder Clinical Director ReghuR.Kunnath MBA - Biomedical & EE

CEO CFO

Chief Marketing Officer Dr.Dave Singh,DMD,PhD,DDSc Incoming President Dr.Tyler Jensen 250 Start-Ups Dan Greenwald Founder&Creative DirectorofWhiteRhino

StimcoreTeam,Board & AdvisoryBoard

Key Members

Dr.Patrick K. Griffith MD, FACS, MBA Cardiothoracic Surgeon Larry Stevens JohnEvey J. PeterMcBride Strategic Healthcare Advisor Joel Michel BM Bus.Strategy&Capital Dr.Sanjay D. Bhojraj Cardiologist

• Global Opportunity

• Reverse and Prevent SBDand OSA

• Accessible Practice Level Solution

• Exclusive License and Patents Pending

• Conservative Financial Projections

Exceed $1 Billion in 5 Years

$5M Capital Raise (Seed Round)

Chief Executive Officer

Toohey,

drblair@stimcoremd.com Stimcore

Dr. Blair Bittner

•••

Thank You

Toohey

“The greatest threat to our healthcare system is the belief that someoneelse will save it.”

S.

Data that’s driving Stimcore…

BEFORETREATMENT TotalVolume:9.4cc / Min Area: 38.0mm2 AFTER TREATMENT Total Volume: 16.8cc/ Min Area: 199.5mm2 Total Volume: 178% Change / Min Area: 523% Change vs Before Treatment BEFORETREATMENT Total Volume:10.9cc/ Min Area:108.4mm2 AFTER TREATMENT Total Volume: 29.8cc/ Min Area: 339.2mm2 Total Volume: 264% Change / Min Area: 312% Change vs Before Treatment

Market Sizeand Value: The OSA Market Alone Is$2.3BPer Year (54 MillionAmericans)

(CAGR 7% per year)

Potential Market For Stimcore (Future) U.S. and Canadian market for Stimcore. (25Years of Sales)

Total Addressable Market

The worldwide CPAP market is valued at $4.3B per year.

Serviceable Addressable Market

54 Million People (US)

54 Million people in the USAsuffer from OSA. TheUSCPAPmarket is valued at $2.3B per year.

Serviceable Obtainable Market

$2B # Cases 1,008,000 First 5 Years of Sales

Direct access to 20 Million patients. 1st 16 months of sales projected (48,000 cases) at $105,600,000

5th year projected (384,000 cases) at $844,800,000

TAM

PAM $69B

SOM Market

1BPeople

SAM

Size

Go-To-Market Strategy Land & Expand

Dental Consultantsand DSO officeswilldrive Stimcore’sbrand and B2B marketing and sales model 01 15States 100,000 Dentists Key Dental Markets 02 90 Dental Consultants 4,000 DSO Offices 6,000 Advisors B2B 03 Dental Consultants DSOs WhiteRhino B2B 04 CMO Dan Greenwald WhiteRhino FortuneMgmt. LVI-SPEAR 1,000 (D) x 48 cases x $180 = $8,640,000 paid to the consultants